Evidence map›Paper›PMID 36833186›Full record

ReviewGenes2023

Progress of Endogenous and Exogenous Nanoparticles for Cancer Therapy and Diagnostics.

Hideaki Fujita, Seiichi Ohta, Noriko Nakamura, Masaharu Somiya, Masanobu Horie

Abstract readReview
In one paragraph

Review in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hideaki FujitaDepartment of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Minami-ku, Hiroshima 734-8553, Japan.ORCID 0000-0003-3430-5681
Seiichi OhtaInstitute of Engineering Innovation, The University of Tokyo, 7-3-1 Hongo, Bunkyo ku, Tokyo 113-8656, Japan.
Noriko NakamuraInstitute of Engineering Innovation, The University of Tokyo, 7-3-1 Hongo, Bunkyo ku, Tokyo 113-8656, Japan.ORCID 0000-0002-0037-8973
Masaharu SomiyaSANKEN (The Institute of Scientific and Industrial Research), Osaka University, 8-1 Mihogaoka, Osaka 567-0047, Japan.ORCID 0000-0002-5607-8128
Masanobu HorieDivision of Biochemical Engineering, Radioisotope Research Center, Kyoto University, Yoshida-Konoe-Cho, Sakyo-ku, Kyoto 606-8507, Japan.ORCID 0000-0001-9795-2582

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The focus of this brief review is to describe the application of nanoparticles, including endogenous nanoparticles (e.g., extracellular vesicles, EVs, and virus capsids) and exogenous nanoparticles (e.g., organic and inorganic materials) in cancer therapy and diagnostics. In this review, we mainly focused on EVs, where a recent study demonstrated that EVs secreted from cancer cells are associated with malignant alterations in cancer. EVs are expected to be used for cancer diagnostics by analyzing their informative cargo. Exogenous nanoparticles are also used in cancer diagnostics as imaging probes because they can be easily functionalized. Nanoparticles are promising targets for drug delivery system (DDS) development and have recently been actively studied. In this review, we introduce nanoparticles as a powerful tool in the field of cancer therapy and diagnostics and discuss issues and future prospects.

Indexed as

Extracellular VesiclesNanoparticlesNeoplasmsCell CommunicationDrug Delivery SystemsHumansDDSextracellular vesicleimaging

Identifiers

PMID36833186
PMCPMC9957423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.